Drug development

#Cardiomyopathy #Drug development #Drug discovery #FDA #HAYA Therapeutics #nHCM #RNA therapy #Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) #US Food and Drug Administration (FDA)

Treatment underway for nonobstructive hypertrophic cardiomyopathy 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).   The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May.  HTX-001 is a… Read More

#News

FDA headquarters
#Biopharma #Drug development #FDA #Interview #Regulatory #United States

Is it harder to align with FDA expectations within pharma in 2026?  

DDW Editor Reece Armstrong speaks to David Crean, Chief Business Officer of biopharmaceutical company MediciNova, about recent turmoil within the FDA and what the pharma sector should expect from the agency going forward.  It’s been a volatile couple of years for the United States. President Trump’s second term has brought with… Read More

#Exclusive Content

Dollar sign on a tablet
#Clinical trial #Drug development #Drug discovery #Investment

The changing landscape for drug discovery investment

As DDW launches its new event series Drug Discovery Innovators & Investors, Lu Rahman looks at the challenges and opportunities that exist for both drug developers and investors looking to bring a new drug to market.  It’s no news that the discovery and development of a new drug is not only costly and lengthy - over $1… Read More

#Business & Investment #Exclusive Content

#AI / data analytics / healthtech / informatics #Clinical trials #Drug development #Drug discovery

AI in clinical data management: What actually works 

By Sandy Tammisetty, VP of the Veeva Services Practice Group at Conexus Solutions.  Artificial intelligence (AI) is no longer a future concept in clinical trials. It is already influencing how clinical data is reviewed, monitored, and analysed, particularly as trials become more complex and data volumes continue to grow. From anomaly detection to advanced… Read More

#Exclusive Content

Cholesterol test
#Cholesterol #Drug development #Heart disease #University of California San Diego

Hidden pathway could be targeted to reduce heart disease 

A hidden biological pathway could be targeted to reduce cholesterol-related heart disease, research shows.  A team from the University of California San Diego School of Medicine uncovered a biological pathway involving the liver, explaining why high-cholesterol diets impede the body’s ability to clear harmful low-density lipoprotein (LDL)… Read More

#News

#CatSci #CRISPR #Drug development #Drug discovery #Life science #siRNA

From undruggable to inevitable

Dr Joe Renny, Head of Corporate Development, and Dr Simon Tyler, Chief Commercial Officer, CatSci, discuss the last 15 years of drug development, and what comes next. The American Cancer Society’s 2026 statistics tell a story that should be on the wall of every drug developer. Five-year survival for chronic… Read More

#Exclusive Content

#AI #Drug development #Sofinnova Partners

Ingenix raises €13m to scale AI drug development model 

AI company Ingenix has announced it has raised €13 million to scale its drug development model.  Ingenix says its Biological Reasoning Engine overcomes structural problems in AI drug development, integrating best-in-class models across modalities and biological scales.  The model was applied to a dual-payload ADC prioritisation… Read More

#News

#3D modelling #Drug development #Oncology #Organoids

Rewriting the Oncology Playbook

Dr Mark Eccleston, Director of Inaphaea, discusses how patient-derived 3D models can bridge the translational divide in oncology.  Drug development is a complex, costly, and time-consuming process with a high failure rate. Effective cancer therapy development in particular, remains challenging with only 3.4% of drugs entering clinical trials between 2000 and 2015 reaching… Read More

#Exclusive Content

Human heart
#Cardiovascular disease #Drug development #Heart disease #Preclinical development

Human-first heart development

Ronald A Li, CEO and Co-Founder at Medera, explores how human-centred preclinical models are transforming cardiovascular drug development. When we published our previous article in Drug Discovery World last September, we argued that human-based mini-Heart technology could fundamentally reshape cardiovascular drug development by reducing reliance on animal models and improving translational predictability. That argument, grounded in strong science, ultimately required patient validation.  Today, that validation is emerging at scale.  … Read More

#Exclusive Content

#Drug development #Personalised medicine #Regulatory

How is the regulatory landscape shaping drug development?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Robert Albarano and Kristina Capiak from Arthur D Little, who have experience maximising commercial success of drug discovery portfolios and securing FDA designations. Bruno speaks to Robert and Kristina about… Read More

#Featured Podcasts #Podcasts

3D protein molecules structure
#Drug development #Drug discovery #Protein degradation #Protein targets

Breaking through the undruggable barrier with TPDs

Alex Bentley, an 1851 Industrial Fellow working with GSK and the University of Strathclyde, discusses how his research into protein degraders will benefit drug discovery efforts across the pharmaceutical industry.  First proposed in the early 2000s, targeted protein degradation (TPD) has emerged as a therapeutic modality with the potential to transform the… Read More

#Exclusive Content

Hematopoietic stem cells in bone marrow.
#Biopharma #Drug development #Drug discovery #Hematopoietic stem cells #Stem cells

Kinetic stem cell counting: a new method to support therapeutic development 

James L Sherley, MD, PhD, explores how a new method for quantifying stem cells in mesenchymal tissue samples can lead to better drug development for stem cell therapies.   Mesenchymal tissue cell samples are considered incredibly promising for the development of new stem cell therapies. These samples can be based on bone marrow,… Read More

#Exclusive Content

Obesity concept
#Drug development #Drug discovery

Read the latest issue of DDW

The new issue of DDW is now on its way to subscribers and available to read online. The Spring issue explores the next phase of obesity medications and asks how US tariffs are impacting global pharma. It also looks at how India is… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Biotech #Drug development #Investment #Market reporting

Treehill Partners: Reflections on JPM and trends for 2026  

DDW Editor Reece Armstrong speaks to Ali Pashazadeh, CEO of capital market company Treehill Partners, about how his experience of this year’s JPM reflects how the industry will move forward in 2026.   The beginning of a new year in drug discovery and development is always marked with the arrival of the JP Morgan Healthcare Conference… Read More

#Business & Investment #Exclusive Content

#AI #Drug development #Legal action

Legal issues arising from the use of artificial intelligence in drug development

Adriana Tibbitts, Alison Lehner, Frank Rahmani, and Jason Kropp from law firm Sidley Austin talk about the legal risks that AI represents in drug discovery and development.      In today’s competitive pharmaceutical industry, drug developers are seeking tools to accelerate development and maximise the commercial potential of their products in a manner that conserves resources and enables them to prioritise their… Read More

#Exclusive Content

#Drug development #Emulate #FDA #SLAS2026

Emulate showcases organ-chip platform at SLAS2026 

Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform.  The AVA Emulation System, launched in June 2025, is a self-contained instrument that cultures, incubates, and images up to 96 independent organ-chip samples in… Read More

#News